The U.S. Food and Drug Administration recently warned that a common gout prescription may increase your chances of death from heart-related issues.
The drug is Uloric (also known as febuxostat), which is commonly prescribed to treat gout. The FDA study concluded that Uloric has an increased risk of cardiovascular death when compared to another gout medicine, allopurinol. As a result of the study, the FDA mandated that all Uloric prescriptions include a “Boxed Warning”—the FDA’s most prominent warning—about the risks of death. Physicians and pharmacists must also give patients a Medication Guide that outlines the risks in writing when prescribing the drug.
Additionally, the FDA is now limiting its approval rating for Uloric. After this study, the FDA will only approve the prescription of Uloric if the patient did not receive effective treatment from allopurinol, or if the patient suffered severe side effects from allopurinol. Based on the results of this new study, the FDA is also warning doctors and health care professionals to only prescribe Uloric for those patients who have failed treatment under allopurinol, or those patients who cannot tolerate it. Effectively, the FDA is mandating that Uloric be only a backup plan because of the drug’s increased risk of death.
Uloric’s History and Gout.
Uloric was first approved by the FDA back in 2009 as a prescription medicine to treat gout in adults. A form of arthritis, gout occurs when uric acid (which is a substance that is naturally present in the body) builds up. This build-up of uric acid can cause swelling, redness and pain in the body’s joints. Uloric was found to be effective in lowing uric acid levels in a person’s blood, mitigating the occurrence and effects of gout.
According to the FDA, citing a National Health and Nutrition Examination Survey, gout affects about 8.3 million adults in the United States. Gout is categorized as a chronic disease, and treatment can be difficult. There are very limited prescription options for treating gout, and, according to the FDA, the means for treating this disease are unmet by currently available options.
The Study and its Findings.
When Uloric was approved in 2009, the FDA included a warning about its potential negative impact on cardiovascular health. In its “Warning and Precaution” about Uloric published alongside the drug’s approval, the FDA highlighted that a serious side effect of the drug was possible cardiovascular events, such as heart attack and stroke.
Therefore, upon the drug’s approval, the FDA also mandated that the drug’s manufacturer, Takeda Pharmaceuticals, conduct a large safety clinical trial to explore the risks of cardiovascular death from the drug. The resulting clinical trial examined more than 6,000 patients who were either taking Uloric or the alternative drug, allopurinol, to treat their gout. The results show that patients taking Uloric had an increased risk of heart-related death, as well as risk of death from all causes. The study noted patient outcomes including heart attacks, stroke, heart-related death, and unstable angina, a condition caused by insufficient blood flow to the heart.
What Should You Do If You Suffer from Gout?
If you are an adult who has been diagnosed with gout, be aware of the risk of death from the drug Uloric. Speak with your physician or health care professional about your prescription choice, particularly if you have a history of stroke or heart issues. However, if you are currently taking Uloric, the FDA warns that you should not stop without first talking to your doctor; cutting off your medication can worsen your gout.
If you are currently taking Uloric, be aware of signals of cardiovascular problems, such as irregular heartbeat, dizziness, chest pain, shortness of breath, numbness on one side of your body, rapid heartbeat or a sudden severe headache. If you experience any of these symptoms, seek emergency medical attention right away.
Interstitial Cystitis Patient Suffers Progressive Visual Deterioration from Elmiron Treatment
After being treated for bladder pain syndrome with pentosan polysulfate sodium (sold under the brand name Elmiron) for two years, a woman in Texas says she experienced progressive vision problems that eventually led to blindness.
According to court filings, the patient began taking Elmiron in 1997 and less than two years later began to experience blurred vision and having trouble with her eyes adjusting in dim lighting. In 2002, she was diagnosed with maculopathy. Additional medical notes showed that pigment changes were also present on the macula of both eyes.
Unfortunately, in 2010, doctors determined the patient was legally blind from macular degeneration and in 2013, she was further diagnosed the eye disease pigmentary retina dystrophy, which is typically characterized by colored spots on the retina.
Elmiron Research Warns of Potential Eye Damage Complications
The patient and her physicians did not know that Elmiron could cause vision damage, as there were no warnings indicating adverse vision events and the first major study connecting the bladder pain drug to vision damage wasn’t published until 2018.
In that study, published in 2018 in the Journal of Urology physicians from the Emery Eye Center noted eye damage and vision problems in six patients who had been treated with Elmiron. More studies followed regarding the association between eye damage and use of Elmiron.
Elmiron Warning Label Changes Delayed in the U.S.
In 2019, the European Medicines Agency required Elmiron maker Janssen to update the label to warn of the potential for eye damage. Health Canada required the same warning label update later the same year. However, it wasn’t until June 2020 that Janssen updated the U.S. warning label to alert the medical community that pigmentary maculopathy had been identified in Elmiron patients.
In October 2020, the Texas patient was diagnosed by a retinal specialist with chorioretinal degeneration and noted significant pigment changes to the retinal tissue and diffuse outer retina atrophy, elements of Elmiron toxicity.
The patient and her husband are seeking damages for the serious injuries the wife allegedly suffered due to use of Elmiron. The claim was filed in the U.S. District Court for the Eastern District of Pennsylvania.
Elmiron Linked to Vision Damage
New studies indicate that the drug Elmiron, a medication already linked to health issues, may also cause vision problems in women with long-term use. The medication is often prescribed as treatment for urinary tract infections as well as osteoarthritis and other conditions.
Studies on Eye Damage
Several studies have been done on the side effects of Elmiron with more investigations underway. Information links Elmiron and vision damage. The amount of damage correlates with the quantity of the medication taken.
Elmiron was approved by the US Food and Drug Administration (FDA) to treat interstitial cystitis, which is a chronic condition of the bladder. It can cause pressure in the bladder along with pain. With long-term use, research indicates that it may be possible for Elmiron to cause pigmentary maculopathy.
This condition impacts the part of the retina known as the macula, which is the central part of the eye. It can cause issues with changes to light. The job of the macula is to protect the retina from UV light, which allows the person to see details better.
The Emory Eye Center, based in Atlanta, GA, made a report that showed that patients who had been taking the drug for about 15 years had changes in their macula. Another 10 patients had a diagnosis of interstitial cystitis and had been prescribed Elmiron. They also showed symptoms that corresponded with pigmentary maculopathy.
Another study was done by Kaiser Permanente which showed that about 24 percent of patients who had been prescribed Elmiron for a minimum of five years had damage to the eye.
Signs of Damage to the Eye
Symptoms associated with this condition include the following:
- Vision loss
- Difficulty with reading
- Vision that is distorted
While the condition can be preventable, it may not be treatable if it develops. This condition is just the latest to be related to Elmiron. Other conditions include the following:
- Optic neuritis and
- Retinal hemorrhage
Even after the patient discontinues the mediation, damage may occur. They may have difficulty adapting to an environment with low lighting. The condition can mimic macular degeneration in its later stages.
Anyone experiencing these symptoms after taking Elmiron should talk to their doctor about treatment. While it is never advised to stop taking prescription medication without consulting with their doctor first, it is important to arrange an appointment to discuss their symptoms with a medical professional right away. If they have taken Elmiron in the past and are experiencing vision changes, they will want to present that information to their doctor.
As the only FDA-approved treatment for IC, it must be continually taken, which means that thousands of patients may have been using Elmiron for years or even decades without knowing about the potential for vision damage. Even with the studies being conducted, Janssen Pharmaceuticals failed to warn the public until regulatory agencies applied pressure. Even when warnings were required in Europe and Canada, no changes were made to the labels in the US until June 2020. It is expected that more people will come forward with evidence of vision damage as the public becomes aware of the situation.
Changes in Priority List for COVID-19 Vaccine
Supplies for the COVID-19 have been limited in California. At this time, only health care workers, staff and residents in long-term care facilities have been getting it as well as people who are age 65 and older. However, the list for who may be top priority in the future could be changing in the state.
Governor Gavin Newsom has announced who will be top priority for the next phase of vaccination. The plan is to switch to an approach based on age. This is a change from the earlier tier plan where workers who were in commercial and residential settings as well as those who were in transportation and manufacturing would be the next priority. It also included homeless people and those who are incarcerated.
No details about how the groups would be divided by age have been given. Some speculate that it may start with those age 50 and up. Many groups have pushed to have these changes made. However, there are other groups who don’t support the age-based approach. Labor unions are critical because they say essential workers should be protected by getting access to the vaccine right away since they are put at risk for doing their jobs.
Groups that support people with disabilities say that those who are at highest risk aren’t being prioritized. The changes don’t consider those who have the most risk for complications with the virus.
When Vaccinations Will Occur
California state officials have indicated that it may be June before everyone who is 65 and older have been able to get the vaccine. The state is getting about 300,000 to 500,000 doses per week. For Los Angeles County, that many doses would be needed each week just to get the adult residents vaccinated by the middle of summer. It is expected that it will be mid-2022 before everyone is vaccinated.
When it comes to priority by industry, healthcare workers are the top priority. Teachers come next because they are the key to getting schools open again for in-person learning. After teachers, it is workers based in the food and agriculture industries with those in emergency services coming next. There is no current timeline for when those workers are able to sign up for vaccinations.
Vaccinations are going slow in part because a significant portion are going to people getting their second dose. That takes away from those who are seeking their first dose. Adding to the complications is the weather. In Orange County, strong winds caused the Disneyland vaccine site to close, which made thousands of people have to reschedule.
Right now, residents age 65 and older are able to sign up for appointments for vaccination in the state. The goal for Orange County is to get all residents their vaccinations by July 4th. Ventura County is allowing residents age 75 and older to sign up for the vaccine. Other counties have their own restrictions for the vaccine and vaccination sites set up for administration based on the number of doses they receive.
Defective Products1 year ago
Dehumidifier Recall: Several Brand Name Humidifiers are Recalled as a Fire Hazard
Medical Devices2 years ago
Complications from Hernia Mesh
Covid-199 months ago
Metformin as Potential Protector from COVID-19
Covid-195 months ago
Moderna Seeks Emergency Approval for COVID Vaccine
Prescription Drugs5 months ago
Recall for Drug Mix-up with Serious Effects
Prescription Drugs7 months ago
Senate Bill May Give More Authority to the FDA for Drug Recall
Prescription Drugs8 months ago
Some Heart Meds May Come with Extra Risk
Covid-199 months ago
FDA Adds Nearly Two Dozen Drugs to Watch List